Characteristics of E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Patients

Details

• Alternative Title:
  J Ark Med Soc
• Personal Author:
  JAMES, ALLISON E. ; SUTPHIN, BRANDY ; FLEMING, PATRICK ; MCCORMICK, DONALD ; BALAMURUGAN, APPATHURAI
• Description:
  During August-December 2019, 23 persons who received a diagnosis of e-cigarette, or vaping, product use-associated lung injury (EVALI) were reported to the Arkansas Department of Health (ADH); none died. Among Arkansas EVALI patients, most were aged <25 years and white; two-thirds were male. Approximately half of Arkansas EVALI patients were admitted to intensive care units. Among 18 patients who were interviewed, 61% reported using both nicotine and tetrahydrocannabinol in an e-cigarette, or vaping, device during the 90 days preceding illness onset. Clinicians should remain vigilant for EVALI and continue to report cases to ADH.
• Subjects:
  Article
• Source:
  J Ark Med Soc. 117(5):110-112
• Pubmed ID:
  37179818
• Pubmed Central ID:
  PMC10174092
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  117
• Issue:
  5
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:2b9b76798b195427158a97badbe3253cbbb6cc70184e58817aac4b45983e287f
• Download URL:
  https://stacks.cdc.gov/view/cdc/128450/cdc_128450_DS1.pdf
• File Type:
  [PDF - 185.22 KB ]